不良研究所

Scientists argue the criteria we use for diagnosing autism may need revision

Without clear and effective biological tests for autism based on genes, brain or blood measurements, diagnosis today still largely depends on clinical assessment. The standard way of doing this is by observing how the individual fits the criteria for autism listed in gold standard manuals like the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).

Classified as: Neuro, Danilo Bzdok, autism, ACAR News
Published on: 26 Mar 2025

Free, online training program strengthens training and brings specialized care to communities across Quebec

A healthcare telementoring program housed at The Neuro and supported by the is expanding its reach after achieving designation as an ECHO Superhub. Under the direction of Julie Scorah, PhD, this milestone ensures that specialized knowledge reaches underserved communities.

Classified as: ACAR News, Julie Scorah
Published on: 25 Mar 2025

Since becoming only the second Alzheimer鈥檚-modifying drug to gain American FDA approval in 2023, sales of lecanemab, known by its brand name Leqembi, have risen steadily, reaching $87-million USD in the last quarter of 2024.

Classified as: Louis Collins, Alzheimer's, Neuro
Category:
Published on: 18 Mar 2025

NeuRo Genomics Initiative will help better understand rare and aging-related neurological disorders affecting Canadians

A project led by Ziv Gan-Or, MD, PhD, at The Neuro (Montreal Neurological Institute-Hospital) of 不良研究所 and Martine T茅treault, PhD, at Universit茅 de Montr茅al has received more than $8 million to sequence the genomes of 8,700 people, to map the role of genetics in neurological disorders.

Classified as: Ziv Gan-Or
Published on: 18 Mar 2025

$400,000 will fuel public-private collaboration to discover new disease biomarkers

A new project co-led by Thomas Durcan, PhD, Director of The Neuro's Early Drug Discovery Unit, and overseen by Mathilde Chaineau, PhD, the EDDU鈥檚 program manager, will receive $400,000 in support from G茅nome Qu茅bec. In partnership with Nardin Nakhla and Armstrong Murira from the Montreal-based company Simmunome, Durcan and听Chaineau will develop a computational model of amyotrophic lateral sclerosis (ALS) on which to test for new biomarkers and therapeutic targets.

Classified as: Thomas Durcan, ALS, Neuro
Published on: 17 Mar 2025

Five clinicians and scientists at The Neuro have been awarded King Charles III Coronation Medals in recognition of their contributions to our understanding of neurological disease. The Coronation Medal commemorates the Coronation of His Majesty King Charles III as King of Canada. The medal is administered by the Chancellery of Honours at Rideau Hall.

Classified as: Heather Durham, Angela Genge, Guy Rouleau, Heidi McBride, Ron Postuma
Category:
Published on: 14 Mar 2025

Mapping immune cell diversity reveals dexamethasone鈥檚 impact on brain cancer immunotherapy

Swelling caused by brain cancer is a problem that can lead to serious side effects and even death. While controlling swelling is important, a new study shows that a commonly prescribed anti-swelling drug suppresses the immune system for weeks after dosage, inhibiting the body鈥檚 ability to fight the cancer.

Classified as: Charles Couturier, Neuro, brain cancer
Published on: 26 Feb 2025

Projects include important research on Parkinson鈥檚, glioblastoma and dementia

Classified as: Xiaoqian Chai, J茅r么me Fortin, Jean-Baptiste Poline, Adrien Peyrache, Austen Milnerwood, alain dagher, Neuro
Published on: 10 Feb 2025

Academic and industry scientists collaborate on a new method to characterize research antibodies

Classified as: Peter McPherson, Carl Laflamme, Neuro
Published on: 18 Dec 2024

YCharOS antibody characterization platform addresses the 鈥渞eproducibility crisis鈥 in research

An innovative research project led by researchers at The Neuro has been awarded $1.5M by the Government of Quebec through CQDM.

YCharOS is an innovative platform led by neuroscientists Peter McPherson and Carl Laflamme that validates antibody reagents for human proteins.

Classified as: Peter McPherson, YCharos
Published on: 12 Nov 2024

$1M grant from The Weston Family Foundation will pave the way for earlier intervention in REM sleep behaviour disorder and Parkinson鈥檚 disease

REM sleep behaviour disorder (RBD) is an often debilitating condition that causes people to act out in their sleep, sometimes violently. What鈥檚 worse, people with the disorder often go on to develop Parkinson鈥檚 disease.

Classified as: Ron Postuma, REM sleep behaviour disorder, Parkinson's, Neuro
Published on: 8 Nov 2024

$1.14 million from CIHR will resolve treatment roadblocks for rare brain disorders

Gene therapy for rare neurological disorders will move one step forward thanks to a $1.14 million grant from the Canadian Institutes of Health Research (CIHR).

Classified as: Carl Ernst, rare diseases, ataxia, ACAR News
Published on: 23 Oct 2024

Thomas Durcan鈥檚 project will dissect the role of microglia in degenerative conditions, to identify new therapeutic strategies for Alzheimer's treatment

An innovative new program based at The Neuro has received $2.6 million from the CQDM and the Brain Canada Foundation.

Classified as: Neuro, Tom Durcan, Alzheimer's, ACAR News
Published on: 16 Oct 2024

MRI data from large sample shows increased whole-brain connectivity in people with a second language

Neuroplasticity is the brain鈥檚 ability to build connections within itself, adapting to the surrounding environment. The brain is most plastic in childhood, forming new pathways in reaction to stimuli such as language.

Classified as: Neuro, MNI, cognition, ACAR News
Published on: 11 Oct 2024

Scientists use stem cells to follow development of protein bodies characteristic of neurological disease

Classified as: Peter McPherson, Parkinson's, Neuro, MNI
Category:
Published on: 8 Oct 2024

Pages

Back to top